ZBIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

4 Analyst Rating

Wall Street analysts forecast ZBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBIO is 43.00 USD with a low forecast of 37.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 32.590

Low

37.00

Averages

43.00

High

46.00

Current: 32.590

Low

37.00

Averages

43.00

High

46.00

Morgan Stanley

Judah Frommer

Overweight

maintain

$34 -> $37

2025-11-13

Reason

Morgan Stanley

Judah Frommer

Price Target

$34 -> $37

2025-11-13

maintain

Overweight

Reason

Morgan Stanley analyst Judah Frommer raised the firm's price target on Zenas BioPharma (ZBIO) to $37 from $34 and keeps an Overweight rating on the shares after the company reported its Q3 update. The "highly anticipated" Phase 3 INDIGO results in IgG4-RD expected around year-end "should offer another opportunity for positive share inflection" if obexelimab data are competitive with Amgen's (AMGN) Uplizna, the analyst tells investors.

H.C. Wainwright

Buy

upgrade

$30 -> $44

2025-10-28

Reason

H.C. Wainwright

Price Target

$30 -> $44

2025-10-28

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Zenas BioPharma to $44 from $30 and keeps a Buy rating on the shares. The firm says obexelimab achieved the primary endpoint of 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions versus placebo in the Phase 2 MoonStone trial.

Citi

Buy

upgrade

$27 -> $46

2025-10-28

Reason

Citi

Price Target

$27 -> $46

2025-10-28

upgrade

Buy

Reason

Citi raised the firm's price target on Zenas BioPharma to $46 from $27 and keeps a Buy rating on the shares. The company reported "strong" Phase 2 MoonStone results for obexelimab in relapsing multiple sclerosis that outperformed expectations, the analyst tells investors in a research note. Citi believes the bull case for obexelima is playing out.

Morgan Stanley

Overweight

maintain

$31 -> $34

2025-10-28

Reason

Morgan Stanley

Price Target

$31 -> $34

2025-10-28

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Zenas BioPharma to $34 from $31 and keeps an Overweight rating on the shares after the company reported 12-week data from the Ph2 MoonStone trial of obexelimab in relapsing MS. 24-week data due in Q1 of 2026 will inform further development, the analyst noted.

Morgan Stanley

Overweight

Buy

downgrade

$35 -> $31

2025-07-03

Reason

Morgan Stanley

Price Target

$35 -> $31

2025-07-03

downgrade

Overweight

Buy

Reason

Morgan Stanley assumed coverage of Zenas BioPharma with an Overweight rating with a price target of $31, down from $35. Upcoming readouts in 4Q25 the first half of 2026 could demonstrate the potential of inhibiting B cells in autoimmune conditions while building out the pipeline-in-a-product potential of obexelima, the analyst tells investors in a research note.

Wedbush

Martin Fan

Buy

Initiates

$35

2025-03-20

Reason

Wedbush

Martin Fan

Price Target

$35

2025-03-20

Initiates

Buy

Reason

Wedbush initiated coverage of Zenas BioPharma with an Outperform rating and $35 price target.

Valuation Metrics

The current forward P/E ratio for Zenas Biopharma Inc (ZBIO.O) is -11.70, compared to its 5-year average forward P/E of -4.03. For a more detailed relative valuation and DCF analysis to assess Zenas Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.03

Current PE

-11.70

Overvalued PE

-1.22

Undervalued PE

-6.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.94

Current EV/EBITDA

-8.49

Overvalued EV/EBITDA

0.73

Undervalued EV/EBITDA

-4.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

33.63

Current PS

34.40

Overvalued PS

75.53

Undervalued PS

-8.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 7114.31% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 7114.31% over the last month.

Sold

Bought

ZBIO News & Events

Events Timeline

No data

News

7.5

12-15Globenewswire

Zenas Acquires Global Rights for Orelabrutinib, Enhancing Multiple Sclerosis Treatment Potential

7.5

12-15Newsfilter

Zenas Acquires Global Rights for Orelabrutinib, Enhancing Multiple Sclerosis Treatment Potential

1.0

11-11Newsfilter

Zenas BioPharma Set to Showcase at Upcoming Healthcare Investment Conferences

People Also Watch

Frequently Asked Questions

What is Zenas Biopharma Inc (ZBIO) stock price today?

The current price of ZBIO is 32.59 USD — it has decreased -19.71 % in the last trading day.

What is Zenas Biopharma Inc (ZBIO)'s business?

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

What is the price predicton of ZBIO Stock?

What is Zenas Biopharma Inc (ZBIO)'s revenue for the last quarter?

Zenas Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Zenas Biopharma Inc (ZBIO)'s earnings per share (EPS) for the last quarter?

Zenas Biopharma Inc. EPS for the last quarter amounts to -1.22 USD, increased 32.61 % YoY.

What changes have occurred in the market's expectations for Zenas Biopharma Inc (ZBIO)'s fundamentals?

The market is revising Downward the revenue expectations for Zenas BioPharma, Inc. (ZBIO) for FY2025, with the revenue forecasts being adjusted by -21.8% over the past three months. During the same period, the stock price has changed by 78.67%.

How many employees does Zenas Biopharma Inc (ZBIO). have?

Zenas Biopharma Inc (ZBIO) has 130 emplpoyees as of December 16 2025.

What is Zenas Biopharma Inc (ZBIO) market cap?

Today ZBIO has the market capitalization of 1.75B USD.